Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB 29 Equity-to-Asset is 0.74 as of Dec. 2025, which is 57% above its 10-year median of 0.47. GuruFocus rates ASX:CMB with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, Cambium Bio ranks better than 57.37% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cambium Bio's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$2.59 Mil. Cambium Bio's Total Assets for the quarter that ended in Dec. 2025 was A$3.49 Mil.
The historical rank and industry rank for Cambium Bio's Equity-to-Asset or its related term are showing as below:
ASX:CMB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -12.32 Med: 0.47 Max: 0.88
Current: 0.74
During the past 12 years, the highest Equity to Asset Ratio of Cambium Bio was 0.88. The lowest was -12.32. And the median was 0.47.
ASX:CMB's Equity-to-Asset is ranked better than 57.37% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASX:CMB: 0.74
Cambium Bio (ASX:CMB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cambium Bio Equity-to-Asset Related Terms
Cambium Bio Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cambium Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cambium Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cambium Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cambium Bio's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a Equity-to-Asset of 0.74 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cambium Bio and its competitors. This is 57% above median its historical median of 0.47. According to the industry distribution chart, Cambium Bio ranks #604 out of 1417 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Cambium Bio's Equity-to-Asset too high?
Cambium Bio's current Equity-to-Asset of 0.74 is 57% above median its 10-year median of 0.47. The Biotechnology industry median Equity-to-Asset is 0.68. Cambium Bio's value of 0.74 is 8.8% above this industry median. Based on the distribution chart, Cambium Bio ranks #604 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cambium Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #604 out of 1417 companies for Equity-to-Asset. This puts Cambium Bio in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Cambium Bio's value of 0.74 is 8.8% above this benchmark. While the company's 10-year median is 0.47 vs. the industry median of 0.68, Cambium Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambium Bio's current Equity-to-Asset of 0.74 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Equity-to-Asset is 0.74, which is 57% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Equity-to-Asset of 0.74. The current Equity-to-Asset is 0.74, which is 57% above median its 10-year median of 0.47 and 8.8% above the Biotechnology industry median of 0.68. Cambium Bio's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Equity-to-Asset is 0.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
29GF Score
Get the complete analysis for ASX:CMB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
